HUE045784T2 - Eliglusztát (Genz 112638) mint glükozilceramid-szintáz inhibitor Fabry- vagy Gaucher-kór kezelési eljárásában történõ alkalmazásra, az eljárás tartalmazza az egyedi terápiás dózisnak a beteg P-450 metabolizmusához történõ beállítását - Google Patents
Eliglusztát (Genz 112638) mint glükozilceramid-szintáz inhibitor Fabry- vagy Gaucher-kór kezelési eljárásában történõ alkalmazásra, az eljárás tartalmazza az egyedi terápiás dózisnak a beteg P-450 metabolizmusához történõ beállításátInfo
- Publication number
- HUE045784T2 HUE045784T2 HUE16175117A HUE16175117A HUE045784T2 HU E045784 T2 HUE045784 T2 HU E045784T2 HU E16175117 A HUE16175117 A HU E16175117A HU E16175117 A HUE16175117 A HU E16175117A HU E045784 T2 HUE045784 T2 HU E045784T2
- Authority
- HU
- Hungary
- Prior art keywords
- eliglustat
- genz
- gaucher
- metabolism
- inhibitor
- Prior art date
Links
- 229960002856 eliglustat Drugs 0.000 title 2
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 title 1
- 208000024720 Fabry Disease Diseases 0.000 title 1
- 208000015872 Gaucher disease Diseases 0.000 title 1
- 108091000114 ceramide glucosyltransferase Proteins 0.000 title 1
- FJZZPCZKBUKGGU-AUSIDOKSSA-N eliglustat Chemical compound C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 FJZZPCZKBUKGGU-AUSIDOKSSA-N 0.000 title 1
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000004060 metabolic process Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26474809P | 2009-11-27 | 2009-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE045784T2 true HUE045784T2 (hu) | 2020-01-28 |
Family
ID=43431870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE14164650A HUE029371T2 (hu) | 2009-11-27 | 2010-11-24 | GENZ 112638 Gaucher- vagy Fabry-kór kombinációs terápiában való kezelésére |
| HUE16175117A HUE045784T2 (hu) | 2009-11-27 | 2010-11-24 | Eliglusztát (Genz 112638) mint glükozilceramid-szintáz inhibitor Fabry- vagy Gaucher-kór kezelési eljárásában történõ alkalmazásra, az eljárás tartalmazza az egyedi terápiás dózisnak a beteg P-450 metabolizmusához történõ beállítását |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE14164650A HUE029371T2 (hu) | 2009-11-27 | 2010-11-24 | GENZ 112638 Gaucher- vagy Fabry-kór kombinációs terápiában való kezelésére |
Country Status (41)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| HUE029371T2 (hu) | 2009-11-27 | 2017-02-28 | Genzyme Corp | GENZ 112638 Gaucher- vagy Fabry-kór kombinációs terápiában való kezelésére |
| CN103764824B (zh) * | 2011-06-20 | 2018-04-24 | 西奈山医学院 | 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法 |
| HUE051021T2 (hu) | 2011-09-07 | 2021-01-28 | Sinai School Medicine | Ceramidáz és sejtek differenciálódása |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| DK2854910T3 (da) | 2012-06-01 | 2020-05-04 | Icahn School Med Mount Sinai | Ceramidniveauer i behandling og forebyggelse af infektioner |
| CA2905449A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
| AU2014321397C1 (en) * | 2013-09-20 | 2019-08-01 | Biomarin Pharmaceutical Inc. | Glucosylceramide synthase inhibitors for the treatment of diseases |
| CA2954030A1 (en) * | 2014-07-03 | 2016-01-07 | Dr. Reddy's Laboratories Limited | Amorphous form of eliglustat hemitartarate |
| WO2016166170A1 (en) | 2015-04-14 | 2016-10-20 | Sandoz Ag | Crystalline eliglustat hydrochloride |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| MX2018006250A (es) | 2015-11-18 | 2018-09-05 | Genzyme Corp | Biomarcador de enfermedad poliquistica renal y usos del mismo. |
| CN107445938B (zh) * | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| CN106349210A (zh) * | 2016-08-24 | 2017-01-25 | 北京阳光诺和药物研究有限公司 | 一种制备酒石酸艾力骨司坦的方法 |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| WO2018193090A2 (en) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
| WO2018225085A1 (en) | 2017-06-05 | 2018-12-13 | Cipla Limited | Stable solid dispersions of eliglustat hemitartrate |
| JP7045726B2 (ja) * | 2017-06-16 | 2022-04-01 | ベータ ファーマ，インコーポレイテッド | Ｎ－（２－（２－（ジメチルアミノ）エトキシ）－４－メトキシ－５－（（４－（１－メチル－１ｈ－インドール－３－イル）ピリミジン－２－イル）アミノ）フェニル）アクリルアミドおよびその塩の医薬品製剤 |
| US20200222310A1 (en) * | 2017-08-08 | 2020-07-16 | Kashiv Biosciences, Llc | Pharmaceutical composition comprising eliglustat |
| EP3664798A4 (en) * | 2017-08-08 | 2021-05-05 | Kashiv Biosciences, LLC | PHARMACEUTICAL COMPOSITION WITH ELIGLUSTAT |
| MX2020006272A (es) * | 2017-12-15 | 2020-09-14 | Genzyme Corp | Metodos para tratar la enfermedad de gaucher. |
| WO2019123476A1 (en) * | 2017-12-20 | 2019-06-27 | Sarudbhava Formulations Private Limited | Stable amorphous eliglustat premix and process for the preparation thereof |
| US11760741B2 (en) | 2018-05-02 | 2023-09-19 | Kashiv Biosciences, Llc | Pro-drugs of eliglustat |
| AU2019276882A1 (en) * | 2018-05-27 | 2021-01-14 | Bioasis Technolgies Inc. | Treatment of gaucher disease |
| CN110878079A (zh) * | 2018-12-31 | 2020-03-13 | 北京启慧生物医药有限公司 | 一种高纯度依利格鲁司他的制备方法 |
| CN116120274A (zh) * | 2021-11-12 | 2023-05-16 | 曙方(上海)医药科技有限公司 | 依利格鲁司他可药用盐及其晶型 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311286D0 (en) | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| DE3522475A1 (de) | 1985-06-22 | 1987-01-02 | Kali Chemie Pharma Gmbh | Neue aromatische verbindungen, ihre herstellung und verwendung |
| US5041441A (en) | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
| ZA929008B (en) | 1991-12-13 | 1993-05-21 | Bristol Myers Squibb Co | Piperazinyl- and piperidinyl-cyclohexanols. |
| US5302609A (en) | 1992-12-16 | 1994-04-12 | The Regents Of The University Of Michigan | Treatment of diabetic nephropathy |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| WO1995005177A1 (fr) | 1993-08-13 | 1995-02-23 | Seikagaku Corporation | Remede contre les maladies nerveuses |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| PT742789E (pt) | 1994-02-02 | 2000-12-29 | Liposome Co Inc | Lipossomas e compostos farmaceuticamente activos e metodos para a sua utilizacao |
| CN1152907A (zh) | 1994-06-10 | 1997-06-25 | 生化学工业株式会社 | 2-酰胺基丙醇化合物及其药物组合物 |
| FR2734819B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
| US5916911A (en) | 1995-09-20 | 1999-06-29 | The Regents Of The University Of Michigan | Amino ceramide--like compounds and therapeutic methods of use |
| US20030073680A1 (en) | 1995-09-20 | 2003-04-17 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6255336B1 (en) | 1995-09-20 | 2001-07-03 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6890949B1 (en) | 1999-07-09 | 2005-05-10 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| NO965193L (no) | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
| JP3993908B2 (ja) | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
| JP4140984B2 (ja) | 1995-12-20 | 2008-08-27 | 生化学工業株式会社 | 分化誘導作用を有する薬剤 |
| US5972928A (en) | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
| JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
| JP4176170B2 (ja) | 1997-06-06 | 2008-11-05 | 生化学工業株式会社 | アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬 |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| AU756008B2 (en) | 1998-07-27 | 2003-01-02 | Johns Hopkins University, The | Methods for treating conditions modulated by lactosylceramide |
| US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
| AU774960B2 (en) * | 1999-07-09 | 2004-07-15 | Regents Of The University Of Michigan, The | Amino ceramide-like compounds and therapeutic methods of use |
| KR20020071931A (ko) * | 2000-01-07 | 2002-09-13 | 트렌스폼 파마수티컬스 인코퍼레이티드 | 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석 |
| US6977723B2 (en) | 2000-01-07 | 2005-12-20 | Transform Pharmaceuticals, Inc. | Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions |
| ES2277301T3 (es) | 2000-04-24 | 2007-07-01 | Teva Pharmaceutical Industries Ltd. | Solvato de hemitartrato de zolpidem. |
| US6436987B1 (en) | 2000-06-08 | 2002-08-20 | Pfizer Inc. | Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid |
| US7148251B2 (en) | 2001-01-10 | 2006-12-12 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20020198240A1 (en) | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
| WO2002062777A2 (en) | 2001-01-10 | 2002-08-15 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20040260099A1 (en) | 2001-01-10 | 2004-12-23 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| EP1392826A2 (en) * | 2001-01-18 | 2004-03-03 | MERCK PATENT GmbH | Bifunctional fusion proteins with glucocerebrosidase activity |
| PT2266968E (pt) | 2001-07-16 | 2013-02-25 | Genzyme Corp | Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase |
| EP1281755A3 (en) | 2001-07-31 | 2003-06-18 | Pfizer Products Inc. | Variants of the human cyp2d6 gene |
| JP4316203B2 (ja) | 2001-08-08 | 2009-08-19 | トビラ セラピューティクス インク | 二環性化合物、その製造法および用途 |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US20060217560A1 (en) | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
| US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| WO2004004702A2 (en) | 2002-07-09 | 2004-01-15 | The Scripps Research Institute | Method to inhibit ischemia and reperfusion injury |
| US20050032070A1 (en) | 2003-08-05 | 2005-02-10 | Sebastian Raimundo | Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications |
| ATE504588T1 (de) * | 2004-01-27 | 2011-04-15 | Synthon Bv | Stabile salze von olanzapin |
| CA3113166A1 (en) | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| BRPI0516001A (pt) | 2004-10-13 | 2008-08-19 | Pharmacia & Upjohn Co Llc | formas cristalinas de 3-[5-cloro-4-[(2, 4-difluorobenzil) óxi]-6-oxopirimidin-1(6h)-il]-n-(2-hidroxietil)-4-metilben zamida |
| JP2008519840A (ja) | 2004-11-10 | 2008-06-12 | ジェンザイム・コーポレイション | 糖尿病の処置方法 |
| WO2007038676A2 (en) * | 2005-09-28 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of ladostigil tartrate |
| AU2006297475A1 (en) * | 2005-10-03 | 2007-04-12 | Mallinckrodt Inc. | Process for preparing zolpidem hemitartrate and tartrate polymorphs |
| MX2007016179A (es) | 2006-04-17 | 2008-03-11 | Teva Pharma | Formas cristalinas de o-desmetilvenlafaxina. |
| PL2032134T3 (pl) | 2006-05-09 | 2015-11-30 | Genzyme Corp | Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów |
| KR101271225B1 (ko) | 2006-10-31 | 2013-06-03 | 삼성디스플레이 주식회사 | 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법 |
| TWI314226B (en) | 2006-12-07 | 2009-09-01 | Ind Tech Res Inst | Piezoelectricity-driving optical lens module |
| EP1961765A1 (en) | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| EP2142197A4 (en) | 2007-03-30 | 2010-11-10 | Amicus Therapeutics Inc | PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS |
| WO2008134628A2 (en) * | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2594564B1 (en) * | 2007-05-31 | 2016-09-28 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| DE102007029581B4 (de) | 2007-06-26 | 2020-04-09 | GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) | Kraftfahrzeugdach und Kraftfahrzeugkarosserie |
| US20090299645A1 (en) | 2008-03-19 | 2009-12-03 | Brandon Colby | Genetic analysis |
| WO2009117150A2 (en) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| AU2010323068B2 (en) | 2009-11-27 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
| FR2953139B1 (fr) | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
| TR201816146T4 (tr) | 2009-11-27 | 2018-11-21 | Adverio Pharma Gmbh | Meti̇l-{4,6-di̇ami̇no-2-[1-(2-florobenzi̇l)-1h-pi̇razolo[3,4-b]pi̇ri̇di̇n-3-i̇l]pi̇ri̇mi̇di̇n-5-i̇lmeti̇l}karbamatin farmasöti̇k etken madde olarak kullanima yöneli̇k olarak üreti̇lmesi̇ne yöneli̇k yöntem. |
| HUE029371T2 (hu) | 2009-11-27 | 2017-02-28 | Genzyme Corp | GENZ 112638 Gaucher- vagy Fabry-kór kombinációs terápiában való kezelésére |
| EP2723733A1 (en) | 2011-06-21 | 2014-04-30 | Novartis AG | Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| JP6728842B2 (ja) | 2016-03-24 | 2020-07-22 | オムロン株式会社 | 光学計測装置 |
| CN107445938B (zh) | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| WO2018193090A2 (en) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
-
2010
- 2010-11-24 HU HUE14164650A patent/HUE029371T2/hu unknown
- 2010-11-24 LT LT16175117T patent/LT3133070T/lt unknown
- 2010-11-24 TW TW099140523A patent/TWI586663B/zh active
- 2010-11-24 IL IL310635A patent/IL310635A/en unknown
- 2010-11-24 PL PL19182732T patent/PL3599237T3/pl unknown
- 2010-11-24 CA CA3075788A patent/CA3075788C/en active Active
- 2010-11-24 RS RS20140446A patent/RS53503B2/sr unknown
- 2010-11-24 NZ NZ715108A patent/NZ715108A/en unknown
- 2010-11-24 PT PT191827328T patent/PT3599237T/pt unknown
- 2010-11-24 PL PL10785289T patent/PL2504332T5/pl unknown
- 2010-11-24 LT LTEP14164650.5T patent/LT2796457T/lt unknown
- 2010-11-24 SI SI201030715T patent/SI2504332T2/sl unknown
- 2010-11-24 PL PL14164650T patent/PL2796457T3/pl unknown
- 2010-11-24 EA EA201890254A patent/EA201890254A3/ru unknown
- 2010-11-24 EP EP19182732.8A patent/EP3599237B1/en active Active
- 2010-11-24 CN CN202010962663.7A patent/CN112521367B/zh active Active
- 2010-11-24 JP JP2012541183A patent/JP2013512252A/ja active Pending
- 2010-11-24 CN CN201610218210.7A patent/CN105753846B/zh active Active
- 2010-11-24 UA UAA201207602A patent/UA113491C2/uk unknown
- 2010-11-24 NZ NZ600155A patent/NZ600155A/en unknown
- 2010-11-24 CA CA3140959A patent/CA3140959A1/en active Pending
- 2010-11-24 PT PT107852899T patent/PT2504332E/pt unknown
- 2010-11-24 EA EA201270646A patent/EA023923B1/ru not_active IP Right Cessation
- 2010-11-24 SG SG10201800136QA patent/SG10201800136QA/en unknown
- 2010-11-24 PL PL16175117T patent/PL3133070T3/pl unknown
- 2010-11-24 US US13/511,768 patent/US11458119B2/en active Active
- 2010-11-24 BR BR112012012947A patent/BR112012012947B8/pt active IP Right Grant
- 2010-11-24 ES ES14164650.5T patent/ES2586947T3/es active Active
- 2010-11-24 SG SG10201407881WA patent/SG10201407881WA/en unknown
- 2010-11-24 CA CA2781676A patent/CA2781676C/en active Active
- 2010-11-24 CN CN202010962639.3A patent/CN112521366A/zh active Pending
- 2010-11-24 PE PE2016002590A patent/PE20171255A1/es unknown
- 2010-11-24 RS RS20160645A patent/RS54978B1/sr unknown
- 2010-11-24 KR KR1020187012588A patent/KR20180049255A/ko not_active IP Right Cessation
- 2010-11-24 HU HUE16175117A patent/HUE045784T2/hu unknown
- 2010-11-24 DK DK16175117T patent/DK3133070T3/da active
- 2010-11-24 MX MX2012006083A patent/MX358345B/es active IP Right Grant
- 2010-11-24 EP EP14164650.5A patent/EP2796457B1/en active Active
- 2010-11-24 ES ES19182732T patent/ES2875382T3/es active Active
- 2010-11-24 PT PT161751177T patent/PT3133070T/pt unknown
- 2010-11-24 MY MYPI2019004988A patent/MY192644A/en unknown
- 2010-11-24 TW TW105126084A patent/TWI606827B/zh active
- 2010-11-24 NZ NZ625712A patent/NZ625712A/en unknown
- 2010-11-24 CN CN201610219151.5A patent/CN105777707B/zh active Active
- 2010-11-24 TW TW106124135A patent/TWI656873B/zh active
- 2010-11-24 WO PCT/US2010/057952 patent/WO2011066352A1/en active Application Filing
- 2010-11-24 AR ARP100104348A patent/AR079152A1/es not_active Application Discontinuation
- 2010-11-24 MY MYPI2012002297A patent/MY160542A/en unknown
- 2010-11-24 EA EA201592195A patent/EA029990B1/ru not_active IP Right Cessation
- 2010-11-24 PE PE2012000717A patent/PE20121337A1/es not_active Application Discontinuation
- 2010-11-24 EP EP16175117.7A patent/EP3133070B1/en active Active
- 2010-11-24 ME MEP-2016-163A patent/ME02477B/me unknown
- 2010-11-24 KR KR1020127016671A patent/KR20120115972A/ko active Search and Examination
- 2010-11-24 DK DK14164650.5T patent/DK2796457T3/en active
- 2010-11-24 ES ES16175117T patent/ES2754398T3/es active Active
- 2010-11-24 DK DK10785289.9T patent/DK2504332T4/da active
- 2010-11-24 ES ES10785289T patent/ES2493940T5/es active Active
- 2010-11-24 EP EP10785289.9A patent/EP2504332B2/en active Active
- 2010-11-24 SI SI201031936T patent/SI3133070T1/sl unknown
- 2010-11-24 KR KR1020227040651A patent/KR20220162824A/ko not_active Application Discontinuation
- 2010-11-24 SI SI201031252A patent/SI2796457T1/sl unknown
- 2010-11-24 AU AU2010324810A patent/AU2010324810B2/en active Active
- 2010-11-24 EP EP21160074.7A patent/EP3896069A1/en active Pending
- 2010-11-24 KR KR1020207002751A patent/KR20200013105A/ko not_active IP Right Cessation
- 2010-11-24 PT PT141646505T patent/PT2796457T/pt unknown
- 2010-11-24 RS RS20191404A patent/RS59543B1/sr unknown
- 2010-11-24 CN CN201080061535.XA patent/CN102712629B/zh active Active
- 2010-11-24 KR KR1020157030851A patent/KR102073207B1/ko active IP Right Grant
-
2012
- 2012-05-18 TN TNP2012000237A patent/TN2012000237A1/en unknown
- 2012-05-20 IL IL219892A patent/IL219892A0/en unknown
- 2012-05-23 DO DO2012000141A patent/DOP2012000141A/es unknown
- 2012-05-24 EC ECSP12011926 patent/ECSP12011926A/es unknown
- 2012-05-24 CL CL2012001348A patent/CL2012001348A1/es unknown
- 2012-05-24 CR CR20120277A patent/CR20120277A/es unknown
- 2012-05-24 NI NI201200096A patent/NI201200096A/es unknown
- 2012-05-25 GT GT201200161A patent/GT201200161A/es unknown
- 2012-06-20 MA MA34989A patent/MA33838B1/fr unknown
- 2012-12-14 HK HK12112977.8A patent/HK1172031A1/xx unknown
- 2012-12-14 HK HK15103822.1A patent/HK1203485A1/zh unknown
-
2014
- 2014-08-18 HR HRP20140780TT patent/HRP20140780T4/hr unknown
- 2014-08-28 CY CY20141100690T patent/CY1115880T1/el unknown
-
2015
- 2015-07-06 JP JP2015134942A patent/JP6370264B2/ja active Active
- 2015-11-02 PH PH12015502514A patent/PH12015502514A1/en unknown
-
2016
- 2016-01-13 US US14/994,489 patent/US20160120842A1/en not_active Abandoned
- 2016-02-22 US US15/049,946 patent/US10888547B2/en active Active
- 2016-03-04 JP JP2016041843A patent/JP6452635B2/ja active Active
- 2016-04-22 AU AU2016202591A patent/AU2016202591B2/en active Active
- 2016-08-11 SM SM201600273T patent/SMT201600273B/it unknown
- 2016-08-17 CY CY20161100807T patent/CY1117996T1/el unknown
- 2016-08-17 HR HRP20161038TT patent/HRP20161038T1/hr unknown
- 2016-09-19 DO DO2016000250A patent/DOP2016000250A/es unknown
- 2016-10-12 CL CL2016002589A patent/CL2016002589A1/es unknown
-
2017
- 2017-11-27 AU AU2017265180A patent/AU2017265180B2/en active Active
-
2018
- 2018-06-27 IL IL260299A patent/IL260299A/en unknown
- 2018-08-23 EC ECSENADI201863798A patent/ECSP18063798A/es unknown
- 2018-09-07 JP JP2018167432A patent/JP7150528B2/ja active Active
-
2019
- 2019-09-12 HR HRP20191647 patent/HRP20191647T1/hr unknown
- 2019-11-13 CY CY20191101196T patent/CY1122698T1/el unknown
-
2020
- 2020-08-14 JP JP2020136889A patent/JP2020189873A/ja active Pending
-
2021
- 2021-01-07 US US17/143,821 patent/US20210369672A1/en active Pending
- 2021-03-18 AR ARP210100682A patent/AR121611A2/es unknown
- 2021-03-18 AR ARP210100683A patent/AR121612A2/es unknown
- 2021-06-13 IL IL283935A patent/IL283935A/en unknown
- 2021-09-03 US US17/465,994 patent/US20210393590A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/865,195 patent/US20230172903A1/en active Pending
-
2023
- 2023-06-21 JP JP2023101301A patent/JP2023116764A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3133070T (lt) | Eligliustatas (genz 112638) kaip gliukozilceramido sintazės slopiklis, skirtas naudoti fabri arba gošė ligos gydymo būde, kur būdas apima individualios terapinės dozės priderinimą paciento p-450 metabolizmui | |
| IL209231A0 (en) | Scoring catheter for treating diseased heart valves | |
| IL234624A0 (en) | Compounds for use as a drug to treat a solid tumor in a patient | |
| HK1163500A1 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| ZA201005363B (en) | Dispenser and therapeutic package suitable for administering a therapeutic dubstance to a subject,along with method relating to same | |
| EP2225002A4 (en) | RNA INTERFERENCE FOR THE TREATMENT OF CARDIAC SUFFICIENCIES | |
| PL2411504T3 (pl) | Komórki ludzkiej tkanki pępowinowej jako terapia choroby Alzheimera | |
| AP2012006339A0 (en) | Methods of administering pirfenidone therapy. | |
| ZA201001015B (en) | (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament | |
| IL204556A0 (en) | (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament | |
| PT2049127E (pt) | Derivados n-metanocarba para tratamento de doenças cardíacas | |
| EP2142254A4 (en) | FEEDBACK CONTROL METHOD FOR ADMINISTRATION OF PHOTODYNAMIC THERAPY AND RELATED INSTRUMENTATION | |
| IL216967A0 (en) | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases | |
| SI2328417T1 (sl) | Spojine, sestavki in postopki za zdravljenje beta amiloidnih bolezni in sinukleinopatije | |
| PL1871399T3 (pl) | Zastosowanie lecytyny jako leku w leczeniu łuszczycy | |
| EP2321816A4 (en) | METHOD FOR PREPARING A PATIENT FOR MEDICAL TREATMENT | |
| WO2009099553A3 (en) | Use of kinase inhibitor in treatment of atherosclerosis | |
| IL260078B (en) | Therapy used to treat Gaucher disease | |
| IL207799A0 (en) | Azetidine-derived compounds, preparation method therefor and therapeutic use of same | |
| EP2398789A4 (en) | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| EP2416776A4 (en) | USE OF TETRAHYDROBIOPTERIN AS A MARKER AND THERAPEUTIC AGENT IN FABRY'S DISEASE | |
| ZA200810199B (en) | Rinse-off therapeutic agents for treating skin | |
| MX2010008433A (es) | Uso de ranolazina para el tratamiento de enfermedades cardiovasculares. | |
| HUP0800498A2 (en) | Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level | |
| IL207668A0 (en) | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain |